pp-258 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Immune disorder, Inflammatory disease, Hematological disease
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Pathway modulator, Immunomodulator, Blood system agent, Ophthalmological agent, Renal system agent, Protein target
Route & form: SC injection / IV infusion
Differentiation: Phase 2, bi-paratopic VHH-Fc fusion protein with two non-competing VHHs conferring picomolar affinity to properdin, a key positive modulator of complement Alternative Pathway (AP);Complement inhibitors have succeeded in rare disease market, with recent penetration into larger indications;Selectively targeting AP has been proved to be safer and more effective, particularly for the treatment of chronic diseases with large population such as IgAN;
Manufacturer #39672
A clinical-stage biopharmaceutical company focused on neurology. Developing a small molecule therapeutic targeting neurology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None